Pharmacotherapy of obesity

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 16, Issue 4, 2002, Pages 717-742

  Finer, N ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

Author keywords

Appetite; Body weight; Cholesterol; Clinical trial; Dexfenfluramine; Diabetes mellitus; Energy expenditure; Fenfluramine; Food intake; Impaired glucose tolerance; Leptin; Metabolic rate; Obesity; Orlistat; Pharmacotherapy; Phentermine; Satiety; Serotonin; Sibutramine; Thermogenesis; Weight loss

Indexed keywords

2,4 DINITROPHENOL; AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BUTABINDIDE; CANNABINOID; CHOLECYSTOKININ; DEXFENFLURAMINE; ENTEROSTATIN; EPHEDRINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; LEPTIN; MAZINDOL; MELANOCORTIN 4 RECEPTOR ANTAGONIST; PHENETHYLAMINE DERIVATIVE; PHENTERMINE; PHENYLPROPANOLAMINE; RIMONOBANT; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID RECEPTOR ANTAGONIST; CHLOROCITRIC ACID; NEUROPEPTIDE Y; THYROID HORMONE; XANTHINE DERIVATIVE; YOHIMBINE;

AORTA VALVE REGURGITATION; APPETITE; BODY WEIGHT; CALORIC INTAKE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIET; DIET RESTRICTION; DISEASE CONTROL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOXICITY; ENERGY EXPENDITURE; FAT INTAKE; FAT MALABSORPTION; FEASIBILITY STUDY; FECAL URGENCY; FECES COMPOSITION; FOOD INTAKE; GASTROINTESTINAL DISEASE; HEALTH HAZARD; HEART VALVE REGURGITATION; HUMAN; HYPERTENSION; INSOMNIA; LIFESTYLE; META ANALYSIS; MITRAL VALVE REGURGITATION; NAUSEA; NERVOUSNESS; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PULMONARY HYPERTENSION; REVIEW; RHINITIS; SATIETY; SIDE EFFECT; SLEEP DISORDER; STROKE; THERMOGENESIS; VALVULAR HEART DISEASE; VERTIGO; WEIGHT REDUCTION; XEROSTOMIA; BRAIN HEMORRHAGE; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG URINE LEVEL; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEAT SENSATION; PROTEIN DEPLETION; SEDATION; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA;

EID: 0036910950     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2002.0231     Document Type: Review

References (154)

1. Kopelman PG & Finer N. Reply: Is obesity a disease? International Journal of Obesity and Related Metabolic Disorders 2001; 25: 1405-1406.
2. Joint Formulary Committee. British National Formulary. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 1994.
3. Joint Formulary Committee. British National Formulary. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 2002.
4. The North American Association for the Study of Obesity. Guidelines for the approval and use of drugs to treat obesity. Obesity Research 1995; 3: 473-478.
5. Kopelman PG, Finer N, Fox K et al. ASO consensus statement on obesity. International Journal of Obesity 1994; 18: 189-191.
6. Scottish Intercollegiate Guidelines Network. Obesity in Scotland. Integrating prevention with weight management. A national clinical guideline recommended for use in Scotland. 1996. Edinburgh, Royal College of Physicians, Scotland.
7. O'Meara S, Riemsma R, Shirran L et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technology Assessment 2001; 5: 1-81.
8. O'Meara S, Riemsma R, Shirran L et al. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: A technology assessment. Health Technology Assessment 2002; 6: 1-97.
9. Bourne J. HC220, 1-66. 15-2-2001. London, The Stationery Office
10. Lessof MH & Myerson A. Benzedrine sulphate as an aid to the treatment of obesity. New England Journal of Medicine 1938; 218: 119-124.
11. Brady JV & Griffiths RR. Testing drugs for abuse liability and behavioral toxicity: Progress report from the laboratories at the Johns Hopkins University School of Medicine. NIDA Research Monographs 1983; 43: 99-124.
12. Munro JF. Clinical aspects of the treatment of obesity by drugs: A review. International Journal of Obesity 1979; 3: 171-180.
13. Hoekenga MT, O'Dillon RH & Leyland HM. A comprehensive review of dieythylpropion hydrochloride. In Garattini S & Samanin R (eds) Central Mechanisms of Anorectic Drugs. New York: Raven Press, 1978.
14. Carabillo EA. USA drug abuse warning network. In Garattini S & Samanin R (eds) Central Mechanisms of Anorectic Drugs. New York: Raven Press, 1978.
15. Griffiths RR, Brady JV & Bradford LD. Predicting the abuse liability of drugs with animal drug self-administration procedures: Psychomotor stimulants and hallucinogens. Advances in Behavioral Pharmacology 1979; 2: 163-208.
16. Munro JF, MacCuish AC, Wilson EM & Duncan LJP. Comparison of continuous and intermittent anorectic therapy in obesity. British Medical Journal 1968; 1: 352-354.
17. Weintraub M, Hasday JD, Mushlin AI & Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Archives of Internal Medicine 1984; 144: 1143-1148.
18. Enzi G, Baritussio A, Marchiori E & Crepaldi G. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. Journal of International Medical Research 1976; 4: 305-318.
19. McLean Baird I & Howard AN. A double-blind trial of Mazindol using a very low calorie formula diet. International Journal of Obesity 1977; 1: 271-278.
20. Scoville B. Review of amphetamine-like drugs by the Food and Drug Administration. In Bray GA (ed.) pp 75-708. Fogarty International Center Series on Preventive Medicine. Washington DC: US Government Printing Office, 1976.
21. Information Centre MCa. Advice for Health Professionals. European Withdrawal of Anorectic Agents/Appetite Suppressants: New Legal Developments, But No New Safety Issues, 2001.
22. Campbell DB. Dexfenfluramine: An overview of its mechanisms of action. Reviews in Contemporary Pharmacotherapy 1991; 2: 93-113.
23. Fuxe K, Hamberger B, Farnebo L-O & Ogren S-O. On the in vivo and in vitro actions of fenfluramine and its derivatives on the central monoamine neurons especially 5-hydroxytryptamine and their relation to the anorectic activity of fenfluramine. Postgraduate Medical Journal 1975; 51 (supplement 5): 35-45.
24. Le Douarec JC, Schmitt H & Laubie M. Pharmacological study of dexfenfluramine and its optical isomers. Archives of Internationales de Pharmacodynamie et de Therape 1966; 161: 206-232.
25. McTavish D & Heel RC. Dexfenfluramine: A review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992; 43: 713-733.
26. Davis R & Faulds D. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 1996; 52: 696-724.
27. Stunkard AJ, Craighead LW & O'Brien R. Controlled trial of behavior therapy, pharmacotherapy, and their combination in the treatment of obesity. Lancet 1980; ii: 1045-1047.
28. Guy-Grand B, Apfelbaum M, Crepaldi G et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989; ii: 1142-1145.
29. Finer N, Finer S & Naoumova RP. Drug therapy after very low calorie diets. American Journal of Clinical Nutrition 1992; 56: 195s-198s.
30. Turner P. Dexfenfluramine: Its place in weight control. Drugs 1990; 39 (supplement 3): 53-62.
31. Sandage BW, Loar SB & Laudignon N. Review of dexfenfluramine efficacy and tolerability. International Journal of Obesity 1994; 18 (supplement 2): P511.
32. Brenot F, Herve P, Petitpretz P et al. Primary pulmonary hypertension and fenfluramine use. British Heart Journal 1993; 70: 537-541.
33. Abbenhaim L, Moride Y & Brenot L. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. New England Journal of Medicine 1996; 335: 609-919.
34. Manson JE & Faich GA. Pharmacotherapy for obesity - Do the benefits outweight the risks? New England Journal of Medicine 1996; 335: 659-660.
35. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. New England Journal of Medicine 1997; 337: 581-588.
36. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. Morbidity and Mortality Weekly Reports 1997; 46: 1061-1066.
37. Khan MA, Herzog CA, St. Peter JV et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. New England Journal of Medicine 1998; 339: 713-718.
38. Weissman NJ, Tighe JF Jr, Gottdiener JS & Gwynne JT. Sustained-Release Dexfenfluramine Study Group. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. New England Journal of Medicine 1998; 339: 725-732.
39. Wadden TA, Silvestry FE, Aber JL et al. Valvular heart disease in fenfluramine-phentermine-treated patients: A comparison with control patients. Obesity Research 1999; 7: 309-310.
40. Shively BK, Roldan CA, Gill EA et al. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999; 100: 2161-2167.
41. Jollis JG, Landolfo CK, Kisslo J et al. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities. Circulation 2000; 101: 2071-2077.
42. Gardin JM, Schumacher D, Constantine G et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. Journal of the American Medical Association 2000; 283: 1703-1709.
43. Loke YK, Derry S & Pritchard-Copley A. Appetite suppressants and valvular heart disease - A systematic review. BMC Clinical Pharmacology 2002; 2: 6.
44. Weissman NJ. Appetite suppressants and valvular heart disease. American Journal of Medical Science 2001; 321: 285-291.
45. Rothman RB & Baumann MH. Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects. Drug Development and Research 2000; 51: 52-56.
46. Darga LL, Carroll-Michals L, Botsford SJ & Lucas CP. Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition 1991; 54: 321-325.
47. Ferguson JM & Feighner JP. Fluoxetine-induced weight loss in overweight non-depressed humans. International Journal of Obesity 1987; 11 (supplement 3): 185-190.
48. Goldstein DJ, Rampey AH Jr, Dornseif BE et al. Fluoxetine: A randomised clinical trial in the maintenance of weight loss. Obesity Research 1993; 1: 92-98.
49. Goldstein DJ, Rampey AH Jr, Enas GG et al. Fluoxetine: A randomized clinical trial in the treatment of obesity. International Journal of Obesity and Related Metabolic Disorders 1994; 18: 129-135.
50. Gray DS, Fujioka K, Devine W & Bray GA. A randomized double-blind clinical trial of fluoxetine in obese diabetics. International Journal of Obesity 1992; 16: S67-S72.
51. Levine AS, Enas GG, Thompson et al. Use of fluoxetine, a selective serotonin uptake inhibitor, in the treatment of obesity. International Journal of Obesity: A Dose-Response Study 1989; 13: 635-645.
52. Levine LR, Enas GG, Thompson WL et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: A dose-response study (with a Commentary by Michel Weintraub). International Journal of Obesity 1989; 13: 635-646.
53. Levine LR, Rosenblatt S & Bosomworth J. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity 1987; 11 (supplement 3): 185-190.
54. Zerbe RL. Safety of fluoxetine in the treatment of obesity. International Journal of Obesity 1987; 11 (supplement 3): 191-199.
55. Silverstone JT. The place of appetite-suppressant drugs in the treatment of obesity. In Stunkard AJ & Wadden TA (eds) Obesity: Theory and Therapy, pp 275-285. New York: Raven Press, 1993.
56. Abell CA, Farquhar DL, Galloway SM et al. Placebo controlled double-blind trial of fluvoxamine maleate in the obese. Journal of Psychosomatic Research 1986; 30: 143-146.
57. Gardiner HM, Freeman CPL, Jessinger DK & Collins SA. Fluvoxamine: An open pilot study in moderately obese female patients suffering from atypical eating disorders and episodes of bingeing. International Journal of Obesity 1993; 17: 301-305.
58. Samanin R & Garattini S. The neuropharmacology of obesity. Reviews in Contemporary Pharmacotherapy 1991; 2: 53-59.
59. Nielsen JA, Chapin DS, Johnson JL Jr & Torgersen LK. Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. American Journal of Clinical Nutrition 1992; 55 (supplement 1): 185S-189S.
60. Ricca V, Mannucci E, Di Bernardo M et al. Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients. Journal of Endocrinology Investigation 1996; 19: 727-733.
61. Brunzell JD. Use of fructose, sorbitol, or xylitol as a sweetener in diabetes mellitus. Diabetes Care 1978; 1: 223-230.
62. Alger S, Larson K & Boyce VL. Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women. American Journal of Clinical Nutrition 1993; 57: 120-126.
63. Morgan JP & Funderburk FR. Invited commentary: Phenylpropanolamine and the medical literature: A thorough reading is required. International Journal of Obesity 1990; 14: 569-574.
64. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Annals of Internal Medicine 1993; 119 (supplement): 707-713.
65. Weintraub M. Phenylpropanolamine as an anorexiant agent in weight control: A review of published and unpublished studies. In Morgan JP, Kagan DV & Brody JS (eds) Phenylpropanolamine: Risks, Benefits and Controversies, pp 53-79. New York: Praeger, 1985.
66. Greenway FL. Clinical studies with phenylpropanolamine: A meta-analysis. American Journal of Clinical Nutrition 1992; 55 (supplement 1): 203S-205S.
67. Lake CR, Gallant S, Masson E & Miller P. Adverse drug effects attributed to phenylpropanolamine: A review of 142 case reports. American Journal of Medicine 1990; 89: 195-208.
68. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. New England Journal of Medicine 2000; 343: 1826-1832.
69. Center for Drug Evaluation and Research. Phenylpropanolamine (PPA) Information Page. 20-2-2002.
70. Prentice AM & Jebb SA. Obesity in Britain: Obesity or sloth? British Medical Journal 1995; 311: 437-439.
71. Kanders BS & Blackburn GL. Health consequences of therapeutic weight loss: Reducing primary risk factors. In Wadden TA & VanItallie TB (eds) The Treatment of Morbid Obesity, pp 213-230. New York: Guilford Press, 1992.
72. Goldstein DJ & Potvin JH. Beneficial health effects of modest weight loss. International Journal of Obesity 1992; 16: 397-415.
73. Committee for Proprietary Medicinal Products. Note for Guidance on Clinical Investigation of Drugs Used for Weight Control. CPMP/EWP/281/96, 1-8. 1977. London, European agency for the evaluation of medicinal products.
74. King DJ & Devaney N. Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers. British Journal of Clinical Pharmacology 1988; 26: 607-611.
75. Halford JC, Wanninayake SC & Blundell JE. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacology and Biochemical Behavior 1998; 61: 159-168.
76. Rolls BJ, Shide DJ, Thorwart ML & Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obesity Research 1998; 6: 1-11.
77. Chapelot D, Marmonier C, Thomas F & Hanotin C. Modalities of the food intake-reducing effect of sibutramine in humans. Physiology and Behavior 2000; 68: 299-308.
78. Connoley IP, Liu YL, Frost I et al. Thermogenic effects of sibutramine and its metabolites. British Journal of Pharmacology 1999; 126: 1487-1495.
79. Seagle HM, Bessesen DH & Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obesity Research 1998; 6: 115-121.
80. Walsh KM, Leen E & Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. International Journal of Obesity and Related Metabolic Disorders 1999; 23: 1009-1015.
81. McNeely W & Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56: 1093-1124.
82. National Institute for Clinical Excellence. Guidance on the Use of Sibutramine for the Treatment of Obesity in Adults. Technology Appraisal 31, 2001.
83. Birkenfield AL, Schroeder C, Boschmann M et al. Paradoxical cardiovascular effects of sibutramine. International Journal of Obesity 2002; 26 (supplement 1): S183.
84. Committee for Proprietary Medicinal Products, 25-27th June 2002 Plenary Meeting Monthly Report. EMEA/CPMP/2749/02/corr, 1-11,2002. London.
85. Bray GA, Ryan DH, Gordon D et al. A double-blind randomised placebo-controlled trial of sibutramine. Obesity Research 1996; 4: 263-270.
86. Bray GA, Blackburn GL, Ferguson JM et al. Sibutramine produces dose-related weight loss. Obesity Research 1999; 7: 189-198.
87. Jones SP, Smith IG, Kelly WF & Gray JA. Long term weight loss with sibutramine. International Journal of Obesity 1995; 19 (supplement 2): 41.
88. James WPT, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. Lancet 2001; 256: 2119-2125.
89. Apfelbaum M, Vague P, Ziegler O et al. Long-term maintenance of weight loss after very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. American Journal of Medicine 1999; 106: 179-184.
90. Griffiths J, Byrnes AE, Frost G et al. Sibutramine in the treatment of overweight non-insulin dependent diabetics. International Journal of Obesity 1995; 19 (supplement 2): 41 (abstract).
91. Fujioka K, Seaton TB, Rowe E et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism 2000; 2: 175-187.
92. Van Gaal LF & Peiffer FW. The importance of obesity in diabetes and its treatment with sibutramine. International Journal of Obesity and Related Metabolic Disorders 2001; 25 (supplement 4): S24-S28.
93. Wing RR, Marcus MD, Epstein LH & Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563-566.
94. Finer N. Sibutramine in clinical practice. International Journal of Obesity and Related Metabolic Disorders 2001; 25 (supplement 4): S12-S15.
95. McMahon FG, Weinstein SP, Rowe E et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Journal of Human Hypertension 2002; 16: 5-11.
96. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94: 152-158.
97. Hauptman JB, Jeunet FS & Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro18-0647 (tetrahydrolipstatin). American Journal of Clinical Nutrition 1992; 55: 309S-313S.
98. Zhi J, Melia AT, Guercolini R et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clinical Pharmacology and Therapeutics 1994; 56: 82-85.
99. Drent ML & Van Der Veen EA. Lipase inhibition: A novel concept in the treatment of obesity. International Journal of Obesity 1993; 17: 241-244.
100. Hartmann D, Hussain Y, Guzelhan C & Odink J. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. British Journal of Clinical Pharmacology 1993; 36: 266-270.
101. Zhi J, Mulligan TE & Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. Journal of Clinical Pharmacology 1999; 39: 41-46.
102. Zhi J, Melia AT, Eggers H et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. Journal of Clinical Pharmacology 1995; 35: 1103-1108.
103. Mulcahy HE & Ballinger AB. Orlistat: A new agent for the treatment of obesity. British Journal of Cardiology 1999; 6: 276-283.
104. McNeely W & Benfield P. Orlistat. Drugs 1998; 56: 241-249.
105. Hvizdos KM & Markham A. Orlistat: A review of its use in the management of obesity. Drugs 1999; 58: 743-760.
106. National Institute for Clinical Excellence. Technology Appraisal Guidance - No 22. Guidance on the Use of Orlistat for the Treatment of Obesity in Adults. 1-12. 1-3-2001. London, National Institute for Clinical Excellence.
107. O'Meara S, Riemsma R, Shirran L et al. A Systematic Review of the Clinical Effectiveness and Cost Effectiveness of Orlistat in the Management of Obesity, 1-121. 2000. London, Report commissioned by the NHS R&D HTA Programme on behalf of The National Institute for Clinical Excellence (NICE).
108. Drent ML, Larsson I, William-Olsson T et al. Orlistat (Ro18-0647), a lipase inhibitor, in the treatment of obesity: A multiple dose study. International Journal of Obesity 1995; 19: 221-226.
109. Finer N, James WP, Kopelman PG et al. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity and Related Metabolic Disorder 2000; 24: 306-313.
110. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. Journal of the American Medical Association 1999; 281: 235-242.
111. Hauptman J, Lucas C, Boldrin MN et al. Orlistat in the long-term treatment of obesity in primary care settings. Archives of Family Medicine 2000; 9: 160-167.
112. Rossner S, Sjostrom L, Noack R et al. European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obesity Research 2000; 8: 49-61.
113. Sjostrom L, Rissanen A, Andersen T et al. European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-172.
114. Keating GM & Jarvis B. Orlistat: In the prevention and treatment of type 2 diabetes mellitus. Drugs 2001; 61: 2107-2119.
115. Heymsfield SB, Segal KR, Hauptman J et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Archives of Internal Medicine 2000; 160: 1321-1326.
116. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002; 346: 393-403.
117. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine 2001; 344: 1343-1350.
118. Mittendorfer B, Ostlund RE Jr, Patterson BW & Klein S. Orlistat inhibits dietary cholesterol absorption. Obesity Research 2001; 9: 599-604.
119. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. Journal of Hypertension 1998; 16: 2013-2017.
120. Lindgrade F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. Journal of Internal Medicine 2000; 248: 245-254.
121. Atkinson RL, Blank RC, Loper JF et al. Combined treatment of obesity. Obesity Research 1995; 3 (supplement 4): 497S-500S.
122. Weintraub M, Sundaresan PR, Madan M et al. Long-term weight control: The National Heart, Lung and Blood Institute funded multimodal intervention study. Clinical Pharmacology and Therapeutics 1992; 51: 581-646.
123. Wadden TA, Berkowitz RI, Womble LG et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial. Obesity Research 2000; 8: 431-437.
124. Pavlou KN, Krey S & Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese individuals. American Journal of Clinical Nutrition 1989; 49: 1115-1123.
125. Astrup A. Thermogenic drugs as a strategy for treatment of obesity. Endocrine 2000; 13: 207-212.
126. Cawthorne MA. Thermogenic drugs. In Björntorp P & Brodoff BN (eds) Obesity, pp 762-777. Philadelphia: JB Lippincott Co,
127. Hoogwerf BJ & Nuttall FQ. Long term weight regulation in treated hyperthyroid and hypothyroid patients. American Journal of Medicine 1984; 30: 681-686.
128. Kong WM, Sheikh M, Lumb PJ et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. American Journal of Medicine 2002; 112(5): 348-354.
129. Lessan NG & Finer N. Is hypothyroidism a cause of obesity? Clinical Endocrinology 1996; 151: (supplement): P106.
130. Malchow-Moller A, Larsen S, Hey H et al. Ephedrine as an anorectic: The story of the 'Elsinore pill'. International Journal of Obesity 1981; 5: 183-188.
131. Lansberg L & Young JB. Sympathoadrenal activity and obesity: Physiological rationale for the use of adrenergic thermogenic drugs. International Journal of Obesity 1993; 17: S29-S34.
132. Astrup A, Breum L, Toubro S et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. International Journal of Obesity 1992; 16: 269-277.
133. Breum L, Pederson JK, Ahlstrom F & Frimodt-Moller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. International Journal of Obesity 1994; 18: 99-103.
134. Daly P, Krieger DT, Dulloo AG et al. Ephedrine, caffeine and aspirin: Safety and efficacy for treatment of human obesity. International Journal of Obesity 1993; 17: S73-S78.
135. Astrup A, Breum L, Toubro S et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A doubt blind trial. International Journal of Obesity and Related Metabolic Disorders 1992; 16(4): 269-277.
136. Arch JRS & Ainsworth AT. Thermogenic and antiobesity activity of a novel β-adrenoreceptor agonist (BRL 26830A) in mice and rats. American Journal of Clinical Nutrition 1983; 38: 549-558.
137. 3-adrenergic receptor - A cause and cure of obesity? New England Journal of Medicine 1995; 333: 382-386.
138. Chapman BJ, Farquahar DL, Galloway SM et al. The effects of a new β-adrenoreceptor agonist BRL 26830A in refractory obesity. International Journal of Obesity 1988; 12: 119-123.
139. Henny C, Schutz Y, Bückert A et al. Thermogenic effect of the new β-adrenoreceptor agonist RO 16-8714 in healthy male volunteers. International Journal of Obesity 1987; 11: 473-483.
140. Mitchell TH, Ellis RDM, Smith SA et al. Effects of BRL 35135, a β-adrenoreceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects. International Journal of Obesity 1989; 13: 757-766.
141. Weyer H & De Souza CJ. Development of β-3 adrenoreceptor agonists as antiobesity and antidiabetes drugs in humans: Current status and future prospects. Drug Development Research 2000; 51: 93.
142. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
143. Rohner-Jeanrenaud F & Jeanrenaud B. Obesity, leptin, and the brain. New England Journal of Medicine 1996; 334: 324-325.
144. Farooqi IS, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency [see comments]. New England Journal of Medicine 1999; 341: 879-884.
145. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 1996; 334: 425-432.
146. Walder K & De Silva A. Leptin and the treatment of obesity. Drug Development and Research 2002; 51: 66-79.
147. Heymsfield SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. Journal of the American Medical Association 1999; 282: 1568-1575.
148. Zimanyi IA & Poindexter GS. NPY-ergic agents for the treatment of obesity. Drug Development and Research 2000; 51: 91-111.
149. Smith GP & Gibbs FP. Satiating effects of cholecystokinin. Annals of the New York Academy of Sciences, 1994; 713: 236-241.
150. Jack DB. Fighting obesity the Franco-British way. Lancet 1996 347(9017): 1756.
151. Levine AS & Billington CJ. Peptides in the regulation of energy metabolism and body weight. In Bouchard C & Bray GA (eds) Regulation of Body Weight: Biological and Behavioural Mechanisms, pp. 179-191. Chichester: Wiley, 1996.
152. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
153. Matsuda LA, Lolait SJ, Brownstein MJ et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
154. Food and Drug Administration. Guidance for the Clinical Evaluation of Weight Control Drugs. Rockville, MD, 1997.